Best push ad networks for CBD and hemp offers in 2026: eight networks ranked for US-only campaigns under the 2018 Farm Bill perimeter

The ranking

Each card carries the verified specs, where the network wins and where it loses on CBD specifically, and the written take on when to choose it.

The CBD push numbers I actually use

Let me show you the numbers. Push CTR for US CBD ran at 1.4–2.6% across my consulting parallel-buy data Q1–Q4 2025 (n=1.8M impressions across 3 affiliate clients, US-44-state geo-blacklisted, SOI free-trial creative). Day-7 CR ran at 0.42–0.78%. The CTR-to-CR Pearson correlation is r=0.21 — slightly tighter than the general push correlation (r=0.18) but still weak. The creative that wins on CTR loses on day-7 CR roughly 38% of the time in the CBD dataset, a marginal improvement over the 41% wider push rate, likely because CBD's compliance-bound creative space narrows the creative variance.

The conversion-latency curve for US CBD SOI is broadly nutra-shaped: roughly 34% of conversions land on day 0, 24% on days 1–3, 21% on days 4–7, 21% on days 8–30. That last 21% is what disappears under a 7-day attribution window — slightly worse than nutra's 17% day-8-to-30 tail. CBD's longer tail is driven by the "first bottle arrives, gets sampled, second bottle ordered" cohort that fires the conversion event on the upsell rather than the initial trial. A 24-hour window captures roughly 58%. A 7-day window captures roughly 79%. A 14-day window captures roughly 93%. CBD specifically benefits more from longer attribution windows than nutra does.

CBD COD (paid-on-delivery shipped bottles) is the other major funnel pattern, and its attribution curve looks different. Day-7 CR runs 0.18–0.34%, day-21 CR runs 0.31–0.52% (n=940K impressions, Q2–Q4 2025, US 44-state compliant). The day-7 to day-21 lift is roughly 1.5–1.8×, driven by the cohort that accepts the package on delivery without refunding it. Running CBD COD on a 7-day window systematically under-reports the format by roughly 35%. The minimum viable attribution window for CBD COD is 21 days server-side; for SOI it's 14 days.

Frequency-cap economics match wider push patterns: 5/day to 3/day reduced impressions 36% and improved CR 0.04pp absolute. Below 3/day on CBD specifically, the impression- cost-per-incremental-conversion ratio runs roughly 4.2× the baseline — slightly worse than wider push (4.0×) because CBD's compliance-bound creative variance is narrower and the diminishing-returns curve on cap reduction is therefore steeper.

Audience-fatigue curve: cohort CR decays -7% to -11% week-over-week from week 4 onward — slightly worse than general push (-6% to -10%) because CBD's creative compliance perimeter narrows the available creative rotation pool. The fix is the same as nutra: rotate publisher inventory every 2–3 weeks while keeping creative stable until CR drops. CBD affiliates who rotate creative weekly without rotating publishers see CR decay match the wider push curve plus an additional 1–2pp on the creative-novelty-loss line.

Regulatory perimeter — Farm Bill, FDA, state law

The 2018 Agriculture Improvement Act (the Farm Bill) legalised hemp federally, defined as Cannabis sativa with ≤0.3% Δ9-THC by dry weight. CBD derived from hemp is federally legal as an ingredient; CBD as a dietary supplement is not currently FDA-approved per FDA's position published 2023 and re-affirmed 2025. The regulatory gap — federally legal as hemp ingredient, not approved as supplement — is what creates the creative-compliance perimeter that affiliate push campaigns operate inside.

FDA's enforceable line is 21 USC §343(r): structure- function claims are permitted with the standard disclaimer; disease-treatment claims are not. Push creative for CBD must avoid disease-treatment language ("cures anxiety," "treats insomnia," "stops pain") and stay within structure-function framing ("supports relaxation," "promotes calm sleep," "supports muscle recovery"). The landing page must carry the full disclaimer ("These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease"). Push creative is too short to carry the full disclaimer, which the FDA has historically accepted when the landing page does.

State-level perimeter as of 2026:

• Hard block (geo-blacklist by default): Idaho, Nebraska, South Dakota. State law restricts CBD products or marketing materially.
• ≤0.1% THC interpretation (creative-specific targeting): Kansas, Mississippi, Wyoming. State THC ceiling stricter than federal 0.3%.
• Permitted, varying age-gate rules: The remaining 44 states. Some require 18+ or 21+ age gating on landing pages; affiliate creative should carry age-disclosure language as a defensive default.
• Delta-8 / Delta-10 banned states (as of 2026): AK, CA, CO, CT, DE, ID, IA, MI, MN, MT, NV, NY, NC, OR, RI, SC, UT, VT, WA — 19 states with material D8/D10 restrictions. D8/D10 creative needs a separate geo-blacklist from the CBD perimeter; treating them as the same compliance perimeter is the most common regulator-flagged failure mode in the vertical.

Networks with state-level geo-targeting handle the 19- state D8/D10 perimeter natively. Networks with country- level US targeting only force the affiliate to handle the state-level blacklist in the landing-page redirect layer, which is operationally brittle — the impression has already fired and been billed by the time the redirect detects the banned state. State-level network targeting is the structurally correct layer for the block, not landing-page redirect.

Why most rankings miss CBD

The CBD push vertical is white-space in published affiliate-marketing rankings for three structural reasons. First, most ranking-site authors are based in jurisdictions (UK, EU, Cyprus, Israel) where US-specific CBD case studies are not legally inhibited to publish, but where the editorial decision is to avoid US-regulator-adjacent verticals because of the perceived legal exposure. Second, the largest US affiliate-marketing publications (the ones that would have the legal team to publish CBD case studies) are advertiser-funded by Meta and Google ecosystems where CBD is a banned category, creating an editorial chilling effect. Third, Mobidea Academy is the one published source with material CBD push case studies (2022–2024) because Mobidea's Cyprus HQ + smartlink-marketplace business model sits outside the editorial constraints that affect US publications and outside the network-direct constraints that affect US-aware networks.

The consequence: most CBD affiliates pick networks based on Mobidea case-study coverage alone, which results in Mobidea winning the CBD push attention by default. The Mobidea case studies are good data — the smartlink marketplace handles state-level routing, the moderation team is CBD-aware, and the Academy team publishes the numbers other networks don't. But Mobidea's smartlink- first model abstracts publisher selection in a vertical where publisher selection is the audit-trail-bearing layer. The affiliate optimising on CBD specifically needs sub-source-ID granularity that Mobidea's smartlink doesn't expose by default. Adsy.tech, RichAds, and PropellerAds all expose deeper sub-source data on a direct-buy basis, even if they publish less CBD-specific case-study content.

How I tested for CBD specifically

Three layers of evidence:

1. Mobidea aggregated dataset (2020–2024). Roughly 14M push impressions on US CBD across the Mobidea book, weighted toward SOI offers (free-trial bottle, $4.95 S&H) with a secondary COD slice. The Mobidea dataset is the baseline reference for day-7 CR distributions, frequency-cap-vs-CR curves, and publisher-quality histograms in the CBD slice specifically.
2. Consulting parallel-buy tests (Q1–Q4 2025). Three CBD affiliate clients, identical free-trial creative across US 44-state geo-blacklisted targeting, identical dayparting and 3/day frequency cap. Networks tested in parallel: adsy.tech, RichAds, PropellerAds, Adsterra, HilltopAds. Measured: actual clearing CPM, day-7 CR, day-21 CR for COD cohorts, state-level impression distribution (to verify blacklist compliance), USDT-rail settlement latency.
3. Panel walkthroughs. For each network I went through campaign-create, state-level targeting configuration, frequency-cap controls, postback configuration for 21-day server-side attribution, publisher-blacklist interface. I asked the AM three standardised questions: "show me per-sub-source CR distribution for last week," "what's the actual state- level impression breakdown on my US targeting," and "how do I set a 21-day server-side postback in five minutes." adsy.tech and RichAds AMs surfaced all three in under fifteen minutes. PropellerAds AM surfaced the state-breakdown only after a manual export request. Adsterra AM provided state-breakdown via a custom report (24-hour turnaround). HilltopAds AM provided on-demand state-breakdown. Mobidea, Monetag, and Mondiad AMs provided country-level breakdowns only — the state-level data has to be reconstructed from IP-geo on the postback log.

Creative-compliance taxonomy — what survives, what doesn't

The push-creative-compliance line for CBD is narrower than for general nutra because the FDA's 21 USC §343(r) structure-function-vs-disease-treatment split is actively enforced. Three creative archetypes I see in the consulting data, with the compliance verdict for each:

Archetype one — "support" frame. "CBD supports your body's natural calm response." "Hemp oil supports restful sleep." "Hemp extract supports muscle recovery after exercise." This is the cleanest compliance frame; structure-function language explicit, no disease-treatment implication. Day-7 CR in my consulting data ran 0.38–0.62% on this frame (n=720K impressions, Q1–Q4 2025), the second-highest of the three archetypes after the symptom-adjacent frame.

Archetype two — "symptom-adjacent" frame. "Feeling tense? Try CBD." "Tossing and turning? Try hemp oil for natural sleep support." The compliance line here is whether the symptom referenced is a recognised disease state ("anxiety," "insomnia") or a general well-being state ("tense," "tossing and turning"). The general well-being framing is permitted; the recognised- disease framing is not. Day-7 CR ran 0.48–0.78% on the permitted symptom-adjacent frame — the highest of the three, because the frame is more conversion- triggering than the abstract support frame while staying inside the compliance perimeter.

Archetype three — disease-treatment frame. "CBD treats anxiety." "Hemp oil cures insomnia." "Stop chronic pain with CBD." This is the violation frame — recognised disease states, treatment-claim verbs, outside the structure-function permitter. FDA enforcement letters cite this archetype most often. Push creative in this frame gets pulled by US-aware network moderation (adsy.tech, Mobidea, Adsterra) at upload; networks moderating from outside the FDA compliance perimeter may let it through and the creative fires until a complaint triggers removal. Affiliates running this archetype are not in a rate-card-and-conversion question — they're in a regulator-exposure question that no network ranking can resolve.

The decision rule for CBD push creative is to write the symptom-adjacent frame first because it outperforms the support frame on CR by roughly 25–35%, and to stay inside the structure-function compliance line by avoiding recognised disease-state language in the symptom referenced. Networks with US-aware moderation teams that flag disease-treatment language at upload are the operational backstop; affiliates moderating their own creative are the primary line of defense.

Sub-source granularity as compliance audit trail

The under-discussed argument for sub-source-ID granularity on CBD specifically is the audit trail. State-level CBD compliance is not a one-time configuration; it's an ongoing demonstration that impressions fired only in permitted states. The configuration may be correct at campaign launch and drift over time as the network's auction routing re-balances. The affiliate's defense, if a merchant audit or regulator inquiry surfaces a banned-state impression, is the postback log showing which sub- source served which impression to which IP-geo state. Networks exposing sub_id1–sub_id5 grain make this defense straightforward; networks aggregating sub-sources into "premium" buckets make it harder to construct.

In my consulting data Q1–Q4 2025, the median affiliate ran roughly 14 sub-sources across the active campaign — the long-tail typical for push at scale. Of those 14, roughly 2 hit a state-level compliance flag at some point in the campaign cycle (e.g., a sub-source publisher whose IP-geo distribution drifted to include a banned state for a 48-hour window before the affiliate's blacklist catch-up). The blacklist-catch-up time matters: on adsy.tech's sub_id1–sub_id5 panel, the median flag-to-blacklist time was 6 hours. On networks with country-level breakdown only, the median was 4–7 days because the affiliate had to reconstruct state-level data from IP-geo postback parsing manually. The compliance-exposure window is the delta — six hours of banned-state impressions vs four-to-seven days of banned-state impressions.

How to pick one for CBD

The disclosed weakness

I commission on adsy.tech signups and not on the other seven networks. Three honest cases where adsy.tech is not the right call:

First: affiliates who've already built scaled CBD push creative inventory and need calendar push or rich- creative push specifically. RichAds' push-format depth is genuinely deeper than adsy.tech's push-as-one-of-9- formats offering. At $1,500–$10K/month spend on CBD push pure, RichAds is the right call. The CBD-specific compliance benefits of state-level targeting and USDT payment apply on RichAds too.

Second: affiliates new to CBD who need published case- study coverage to calibrate expectations. Mobidea Academy's CBD case studies are the most useful entry- point reference in the category. Reading them, running a small test on Mobidea's smartlink to internalise the publisher-quality distribution, then graduating to direct-buy is a defensible path. adsy.tech doesn't publish CBD-specific case studies at Mobidea's depth, so the entry-point friction is real.

Third: affiliates at $5K+/month spend who need an AM with deep CBD-specific campaign history. PropellerAds' AM team has seen more CBD push campaigns than adsy.tech's AMs because PropellerAds has been running US-permitted verticals at scale for longer. The card-rail friction is real, but at $5K+/month, the AM-depth advantage may outweigh the 1–2% conversion cost. Below $5K/month, adsy.tech's lower-friction operational model and AM responsiveness on smaller accounts inverts the answer.

The structural caveat

Every number on this page is from my Mobidea aggregated CBD slice 2020–2024 or my consulting parallel-buy tests Q1–Q4 2025. Sample sizes, GEO mixes, and creative types are annotated. The numbers don't generalise to your offer, your creative, or your audience pool without a confirmation test in your own panel. The methodology — n, GEO, vertical, date, day-7 CR, day-21 CR for COD, frequency cap, sub-source distribution, state-level impression breakdown — is what generalises.

The CBD compliance perimeter shifts. The 2018 Farm Bill is up for reauthorisation in the 2026–2027 legislative cycle. State-level rules in CA, NY, and TX are under active legislative review. The 19-state D8/D10 ban list is a moving target — at least three states have pending legislation as of mid-2026. Any CBD affiliate running push at scale needs a quarterly compliance review with a US attorney specialising in supplement and hemp regulation, not a one-time setup-and-forget targeting configuration. The networks that win this ranking are the ones with state-level targeting and sub-source granularity granular enough to adjust to perimeter shifts within a campaign cycle, not the ones with the best published case studies from 2022.

FAQ

Why push ads for CBD and hemp offers in 2026?

Because Meta, Google, and TikTok still classify CBD as a restricted category despite federal legality under the 2018 Farm Bill. Search and social are mostly closed channels for direct CBD/hemp affiliate work. Push, popunder, and native are the channels where Tier-1 US CBD volume is reachable at scale. Of those three, push delivers the cleanest day-7 attribution for the multi-step CBD funnel — landing → email-capture → first-bottle order — which neither popunder (day-0-skewed) nor native (slower decision window) matches as cleanly.

Which push network is best for CBD in 2026?

adsy.tech on the rate-card-floor + sub-source-granularity + USDT-for-payment-processors combination. CBD affiliates face credit-card-processor instability — most CBD merchants run through high-risk processors that pay in USDT or wire — and the affiliate's commission settlement often follows the same rail. adsy.tech accepts USDT-TRC20 by default with a $50 deposit minimum. The $0.50 CPM floor lets a small-budget test reach the 200-conversion smart-bidding threshold inside $50–$120 of spend, which matters more in CBD where Meta-blocked status means most affiliates start with smaller budgets than they would on a permitted vertical.

Is CBD pushing legal under federal law?

Yes, conditional on three things. First, the product must be derived from hemp containing ≤0.3% THC by dry weight per the 2018 Agriculture Improvement Act (the Farm Bill). Second, the creative cannot make disease-treatment claims — 'cures anxiety,' 'treats insomnia' — only structure-function claims like 'supports relaxation' or 'promotes calm sleep.' Third, the landing page must carry the FDA structure-function disclaimer ('These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.') Compliance failure on any of the three opens 21 USC §343(r) exposure on the merchant and reputational exposure on the affiliate.

Which US states block CBD advertising at the state level?

Idaho, Nebraska, and South Dakota maintain the strictest state-level CBD restrictions as of 2026 — affiliate creative serving impressions in those GEOs runs a take-down risk regardless of federal compliance. Kansas, Mississippi, and Wyoming have stricter THC-percentage interpretations than the federal 0.3% standard. The operational fix: geo-blacklist ID, NE, SD by default, geo-fence KS, MS, WY for ≤0.1% THC products only, and treat the remaining 44 states as the cleanly permitted CBD push market. Most networks (adsy.tech, RichAds, PropellerAds, Adsterra, HilltopAds) support state-level geo-targeting; some (Monetag, Mondiad) only support country-level for US, which forces blacklist work upstream in the creative tagging layer.

Why is Mobidea the only network with public CBD push case studies?

Because Mobidea's Cyprus HQ sits outside the US compliance perimeter that makes US networks cautious about publishing CBD-specific case studies, even when the campaigns are federally compliant. The Mobidea Academy CBD case studies (2022–2024) are the most-cited published push-CBD benchmarks in the category. The downside: Mobidea's smartlink-first model abstracts publisher selection, which is the wrong default for a CBD affiliate who needs to validate every sub-source against the state-level geo-blacklist. Mobidea is the right call when you're learning the format; wrong call when you're optimising CBD specifically.

What CR should I expect on US CBD push in 2026?

Day-7 CR for US CBD SOI (free-trial-bottle offers) runs 0.42–0.78% across my consulting parallel-buy data Q1–Q4 2025 (n=1.8M impressions across 3 affiliate clients, US-44-state geo-blacklisted). For COD-shipped CBD (paid-on-delivery): 0.18–0.34% day-7, 0.31–0.52% day-21 (the cohort that lands and accepts delivery without refunding). The day-7 to day-21 lift on COD CBD is roughly 1.5–1.8× — larger than nutra COD because the CBD return-window cohort skews toward keep-it decisions when the bottle arrives intact. If your network defaults to a 7-day attribution window, you're missing roughly 30% of CBD COD conversion value.

Which payment rails matter for CBD affiliates?

USDT-TRC20, USDT-ERC20, and wire. Credit cards are unreliable for CBD merchant settlement — most CBD merchants run through high-risk processors (Easy Pay Direct, PayKings, NMI gateways with high-risk underwriting) and the affiliate commission settlement often shadows the merchant's rail. Networks accepting USDT (adsy.tech, HilltopAds, Mobidea, RichAds, Adsterra, Mondiad, Monetag) are the practical short list. PropellerAds is card-first, which is a friction point in this vertical specifically — the affiliate gets paid in USDT by the merchant and needs to settle in USDT with the network too, which means a card-only network forces a USDT→card conversion that costs 1–2% on every cycle.

Is hemp Delta-8 / Delta-10 the same compliance story as CBD?

No, and treating it as one is the largest compliance trap in the vertical. Delta-8 and Delta-10 THC are hemp-derived under the 2018 Farm Bill at the federal level but face state-level bans in 15+ states as of 2026 (including CA, CO, NY, OR, WA — the largest US affiliate-traffic GEOs). The federal-legal-state-banned gap is wider for D8/D10 than for CBD. Most push networks will accept D8/D10 creative for compliant states only, and the affiliate is responsible for state-level geo-blacklisting. The compliance audit trail matters more for D8/D10 than for CBD — sub-source-ID granularity is what lets the affiliate prove the impression didn't fire in a banned state if the merchant is audited later.

Related reading

• → Best push ad networks for nutra offers — the wider supplement ranking with FDA, EFSA, UOKiK perimeter detail
• → Push ads vs popunder — which converts better, by vertical and attribution window
• → adsy.tech vs RichAds on push specifically — format depth vs rate-card floor
• → Push-ad glossary — CTR, CR, day-7 attribution, frequency cap, sub-source granularity